Tiziana Life Sciences collaborates with Parexel Biotech

11 November 2020

UK biotech Tiziana Life Sciences (Nasdaq: TLSA) is collaborating with Parexel Biotech, a division of global clinical research organization (CRO), Parexel International (IRL), to conduct a global Phase Ib/II trial with enteric-coated capsules of formulated foralumab, the only fully human anti-CD3 monoclonal antibody (MAb) - as a therapy for patients with moderate to severe Crohn’s disease (CD).

This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the USA and Europe, said Tiziana, whose shares were up 6.7% at 103.00 pence in late-morning trading today.

Tiziana and antibody-based drug manufacturer Novimmune entered into an agreement in 2014 whereby Novimmune granted Tiziana an exclusive license for the clinical development and commercialization of foralumab, in a deal valued at around $2 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK